



SAVING SIGHT



**Glaucoma
Australia**
Saving sight

Our Community

20,695
Patients

754
Referring
Practitioners



125
Volunteers

9
Staff

Vision

An Australia free from
glaucoma blindness.

Mission ←

To prevent glaucoma
blindness by increasing
early detection and
improving patient
treatment outcomes.

Our Purpose

Our Purpose is to improve the lives of people with glaucoma and those at risk, by increasing early detection and positive treatment outcomes through education, advocacy, and research. We empower individuals to understand and take an active interest in their own eye health; we promote research, innovation and work collaboratively with health care professionals.

Our Impact

1,748

new patients joined the patient support program


1,658

online support group members

10M+


Australians received glaucoma awareness messaging through PR activities

\$153,313
donated to research



Supported patients Unsupported patients

% of patients who said they always or frequently feel anxious in relation to their glaucoma



Supported patients Unsupported patients

85% of patients supported by Glaucoma Australia are compliant with their treatment regimen

91%

of patients supported by Glaucoma Australia attend their recommended appointments

88%

of patients supported by Glaucoma Australia have informed their direct relatives to get tested



President's Report

I am delighted to deliver the 2022 Annual Report for Glaucoma Australia Incorporated (Glaucoma Australia). Another year with COVID, lockdowns and an acceptance that COVID has become part of our lives.

Once again Glaucoma Australia has adapted continuously to deliver our mission by supporting glaucoma patients and their families. Even with the challenges that COVID and disruptions in many parts of the world have brought, the health and wellbeing of our glaucoma patients, friends, supporters and the team are our priorities. Although it has been a difficult year, Glaucoma Australia has had a significant number of 'wins and good news' stories this year.

Quinlivan Research Grant

Glaucoma Australia is proud to continue to support ground-breaking Australian researchers through our Quinlivan Research Grants.

To commemorate World Sight Day (14 October 2021), Glaucoma Australia and its Patron, the Governor-General of Australia, His Excellency General the Honourable David Hurley AC DSC (Retd), were delighted to award the 2021 Quinlivan Research Grant to Professor Ewa Goldys, from the University of New South Wales' Graduate School of Biomedical Engineering, who has developed a novel imaging technology for the early detection and monitoring of glaucoma.

Professor Goldys, who is a world leading biomedical engineer, and a team of medical and data scientists will work together with internationally recognised glaucoma clinician-scientists Professor Andrew White and Professor Robert Casson, to lead this exciting project on the journey from lab to clinic.

We also continue to provide funding for ongoing research by Professor Jamie Craig and Dr Flora Hui through the Quinlivan Research Grants.

Strategic Plan for 2022

The Board's highest priority in the first half of the year was to develop a new Strategic Plan which was implemented in January 2022. I would like to take this opportunity to thank all board members, the CEO and Professor Ivan Goldberg for participating in the Zoom workshops, and the time commitment of approximately 30 hours outside of business hours that everyone willingly provided. Their commitment and engagement resulted in a Strategic Plan that set new directions and strategic priorities that will enable Glaucoma Australia to better support our patient groups as well as focus on new initiatives for financial sustainability and advocacy.



New Online Store

In the second half of the year, Glaucoma Australia launched its new online store with an expanded product range which now includes low vision aids such as electronic magnifiers, magnifying lamps and talking devices.

The iCare HOME2 Self-Tonometer was introduced following a number of Ophthalmologists encouraging their patients to test their pressure at home. This has been particularly important due to COVID restraints. Revenue from the store will help fund our patient support programs and we look forward to seeing this grow as a valuable revenue stream in the coming years.

Inaugural Fundraiser

Glaucoma Australia launched its inaugural fundraiser - the 7 Sights in 7 Days Challenge - ahead of World Glaucoma Week (6 - 12 March 2022). The event raised an impressive \$121,788 in its first year with funds going towards early detection programs, better treatment outcomes and support services that improve quality of life.

We asked participants to find, snap and share 7 photos of amazing sights. It was fantastic to see all the wonderful photos that remind us how precious our eyesight truly is. Thank you to the Glaucoma Australia team and everyone who participated and raised funds.

Another official ambassador announced

We have been delighted to welcome David "Kochie" Koch as an official ambassador in the lead up to Men's Health Week (13 -19 June 2022). Kochie is one of Australia's best-known personalities, having co-hosted Network Seven's Sunrise for the past 19 years and is now supporting the fight against eye disease by sharing his own glaucoma diagnosis and encouraging Australians to have their eyes checked regularly, as early detection saves sight.



Impact of COVID on the number of eye tests conducted nationally

During an 18-month period that included this year, there were 516,906 less eye tests conducted nationally than in the previous 18-month period. This means that there are more than half a million Australians at greater risk of developing an eye condition or losing sight than before the pandemic.

With around 90% of blindness and vision impairment preventable or treatable if detected early enough, this is the perfect time for everyone to have their eyes tested, even though COVID is still with us.

Social Media Community numbers growing

Glaucoma Australia's Social Media followers have increased during the year with Facebook increasing by 23%; Instagram by 25%; and LinkedIn by 59%. The Support Groups' members have also increased significantly with the Facebook Glaucoma Support Group increasing by 40% and the Congenital Glaucoma Support Group by 27%. The Glaucoma Australia team works diligently with the social media community, especially the Support Groups to deliver information and support. Even though face to face group events were not possible during the year, a total of eleven live Q&A events were held using social media. All events were well attended and received.



Patient Impact Measurement Survey

This year 1,300 people were surveyed which was double the number of people from the 2021 survey. The results were comparable to last year and indicate the areas for improvement. The most notable improvement was the reduction in the percentage of patients who always or frequently experience anxiety about glaucoma after receiving education and support from Glaucoma Australia. This is a very clear example of the value provided by the Patient Support Program.

The results showed that

- 20% of supported patients said they always or frequently feel anxiety about their glaucoma. This is a significant reduction from 44% of patients surveyed when they first join the program.
- 91% always attend their appointments.
- 85% always instil their eye drops.
- 60% rate their knowledge about glaucoma as excellent or above average.
- 88% have asked relatives to get their eyes tested.

Once again, being a trusted and patient-centric organisation has helped us to successfully navigate the challenges that Glaucoma Australia has experienced during this year. As I shared with you last year, our commitment to supporting glaucoma patients and raising awareness remains as strong as ever. We have all come to expect many changes in every aspect of our lives, and once again this year the Glaucoma Australia team has continued to deliver our services by being creative, diligent and always having the glaucoma patients' wellbeing at the heart of everything they do. Thank you to the Glaucoma Australia team that always goes 'above and beyond' to help achieve our Mission.

Board and Executive changes

This year we have had the pleasure of welcoming Dr Katherine Masselos and Satish Chandar to the Board.

Dr Katherine Masselos

Katherine brings expertise in the diagnosis and management of glaucoma. She performs both glaucoma and cataract surgery and has completed a fellowship in glaucoma at the Manchester Royal Eye Hospital in the United Kingdom. Katherine works in private practice in Sydney, is a staff specialist at Prince of Wales and Sydney Eye Hospitals and works with the Outback Eye Service to provide eye care to residents of Broken Hill and surrounding regions. She also lectures at the University of New South Wales and is highly regarded and respected by her peers and patients.

Katherine has been appointed as the Chair of the newly formed Clinical Advisory Panel (CAP) which has brought the Ophthalmology Committee, Optometry Committee and Pharmacy Committee together providing a collaborative, well informed panel of clinicians. She was previously the Chair of the Ophthalmology Committee.

Satish Chandar

Satish brings extensive experience in developing and implementing business strategies and transformation programs across medium to large organisations across multiple geographies in financial services industries as well as in the not-for-profit sector. His interests are in the cross-section of business, technology and digital strategies and advising on the associated challenges and opportunities. He has a strong family history of glaucoma and is keen on supporting early detection and treatment of glaucoma.

Satish has been appointed as the Chair of the Media and Digital Technology Committee (formerly ICT Committee). Satish was a member of the ICT Committee before his appointment as Chair.

Dr Benjamin Ashby

We were also pleased to appoint Dr Benjamin Ashby to the role of Vice-President. Ben has been a member of the Board for several years and brings a significant amount of experience and knowledge in both business and optometry to this new role.

Farewells

James Christensen

The Board farewelled James Christensen who was appointed in 2019. We sincerely thank him for his efforts and wish him well with his expanding business commitments.

CEO – Annie Gibbins

We also farewelled our CEO, Annie Gibbins. Annie spent four and a half years in the CEO role and during this time one of her greatest successes was to bring Glaucoma Australia into the digital age. Her resignation from Glaucoma Australia has enabled her to pursue and further develop her own businesses and new ventures. We wish Annie every success with her business ventures and are very appreciative of her hard work, passion and diligence during her time with Glaucoma Australia. The Board has appointed a new CEO, Richard Wylie commencing July 2022.

I would like to thank the Members, Board, Committees and Professor Ivan Goldberg for the support they have provided to me during the year. Best wishes in these ever-changing times,



Maree O'Brien

“ You manage a wonderful service through Glaucoma Australia and I really appreciate your help, to combat my generalised anxiety in relation to glaucoma.”

– Robert



CEO's Report

My name is Richard Wylie and I am the new CEO at Glaucoma Australia (GA).

Firstly, I'd like to congratulate former GA CEO Annie Gibbins for her successful leadership of the organisation over the past four and a half years. I'd also like to thank Kay Richards for doing a great job as Interim CEO during the period between Annie's departure and my arrival.

I feel very blessed to have been chosen by the GA Board to lead this wonderful organisation into the future. What really excites me about Glaucoma Australia, is the tangible difference we make to people's lives every day and the potential to help many more people in the years ahead. Glaucoma is the leading cause of irreversible blindness both here and around the world. I can't think of a more worthwhile mission in which to apply my passion, experience and creativity into the future.

I have spent many years working in various organisations who have had a strong medical research focus. For that reason, one of the things I admire most about Glaucoma Australia is the organisation's ongoing commitment to supporting local research. Nowhere is this more evident than Glaucoma Australia's Quinlivan Research Grant which is awarded annually to Australia's leading glaucoma researchers. Another goal of mine will be to grow our revenue streams, so we can continue to invest in high quality research into the future.

For me the jewel in the crown at GA is our Patient Support Program. Every day, our trained Clinical Educators support patients throughout their glaucoma treatment journey. Our program data, when compared to published adherence data for typical glaucoma patients, demonstrates patients achieve significantly improved health outcomes when enrolled in our program. For this reason, growing the number of patients who are enrolled in our program will be an ongoing focus for me.

I'd like to take this opportunity to particularly thank our generous donors and our corporate partners. Without you we simply couldn't continue to have the impact that we do in the community. I'd also like to thank our wonderful Board for their endless inspiration and support. And finally, I want to make a special thank you to our passionate and talented staff. Their commitment to our cause of 'saving sight' is remarkable.

Please enjoy this year's Glaucoma Australia Annual Report.

Sincerely,

A handwritten signature in blue ink that reads "Richard Wylie". The signature is fluid and cursive, with a large initial 'R'.

Richard Wylie



PATIENT SUPPORT PROGRAM



One of the most impactful ways Glaucoma Australia influences the eye health of Australians is via our Patient Support Program. Objectives of the program are as follows:

Empower those who have been diagnosed with glaucoma to understand their disease and make **informed decisions** to maintain their quality of life.

- Provide one-on-one emotional support (via our Orthoptist Educators) to help **manage the anxiety** of receiving a glaucoma diagnosis.
- Play a facilitation role within each patient's circle of care, to maximise rates of appointment and treatment adherence.
- **Support** eye health professionals to 'extend their care' beyond the practice, thereby maximising long-term patient treatment outcomes.

**“Appreciated
your warmth,
professionalism
and outstanding
knowledge
of glaucoma.
You answered my
questions with great
respect and in
language I could
comprehend
and process.
Thank you!”**

– Dorothy



Program Features

- Automated email and SMS educational journeys
- Personalised phone calls (both inbound and outbound)
- Free support line: 1800 500 880
- 24-hour webchat on the Glaucoma Australia website
- Website: www.glaucoma.org.au
- Social media: Facebook and Instagram
- YouTube educational films and Q&A Live Events
- 2 online support groups:
 - Glaucoma Australia Support Group (1,367 members)
 - Congenital/Childhood Glaucoma Support Group (291 members)

Key statistics and program insights

Demand for our program is growing, with new patient referrals now 500+ per quarter.

- This represents 1% of all newly diagnosed glaucoma patients in Australia, creating an enormous opportunity to grow the scale and impact of the program in the years ahead.

Common topics discussed during patient support are:

- Glaucoma eye drops – side effects, instillation techniques, storage and traveling with eye drops.
- Options available for treatment – laser, surgery and alternative treatments.

- Living with glaucoma – diet and exercise, other medications and glaucoma, financial impact of ongoing appointments and treatment. Anxiety and glaucoma.

Our most recent patient impact survey (July 2022) confirmed the program's effectiveness:

- Almost 50% of new patients have high anxiety levels due to their glaucoma diagnosis compared to 20% of patients after receiving intervention and support.
- 85% of patients supported by Glaucoma Australia are compliant with their eye drop regimen compared to 50% of unsupported patients after 6 months and 37% after 3 years.
- 91% attend all their recommended glaucoma appointments.

We have significantly increased knowledge of glaucoma and reduced anxiety levels overtime with ongoing check-ins and support calls:

- 60% of patients surveyed rated their knowledge of glaucoma and how it is treated as above average or excellent compared to 34% of patients when they first join the Patient Support Program.
- 20% of patients surveyed said they always or frequently feel anxious in relation to their glaucoma compared to 44% of patients when they first join the Patient Support Program.
- 88% of our patient impact survey respondents have informed their relatives to get tested.

RESEARCH



The 'Quinlivan' Research Grants Program

Since 2006, Glaucoma Australia has funded over 30 grants to support Australian glaucoma researchers across a diverse range of projects. The Glaucoma Australia 'Quinlivan' Research Grant is awarded annually following rigorous evaluation by an independent research panel and makes a significant contribution to the Australian medical research landscape. The research grant program is funded by the William A Quinlivan Research Fund which was established in 2006.

Opposite is a summary of the projects that were funded by Glaucoma Australia during the year up to 30 June 2022.

INDEPENDENT RESEARCH PANEL

Professor Allison McKendrick - Chair
MScOptom, PhD

Clinical Associate Professor Andrew White
BMEDSC(HONS), MBBS, PHD, FRANZCO

Dr George Kong
MBBS (Melb) BMedSci PhD (Melb) FRANZCO

Dr Jennifer Fan Gaskin
MBChB MD FRANZCO

Associate Professor Bang Bui
B.Optom, M.Optom, PhD, PGCOT

Professor Bill Morgan
PhD, MBBS, FRANZCO

Professor Robert Casson
MB, BS(Hons), M. Biostats, DPhil, FRANZCO

Associate Professor Mitchell Lawler
BMed MMed(OphthSci) FRANZCO PhD



Professor Ewa Goldys,
University of New South Wales
2021 Grant Recipient

Professor Ewa Goldys' research project focuses on fluorescent Hyperspectral Imaging technology which is a novel imaging tool for the early detection and subsequent monitoring of glaucoma. The novel technology obtains real time monitoring of disease status by non-invasively obtaining information about retinal energy metabolism. A few months into the study and Professor Goldys has reported the research results are looking very promising. So far, the investigations of retinal cells by using hyperspectral imaging technology show very strong signatures related to glaucoma-simulating interventions.

Dr Flora Hui,
Centre for Eye Research Australia (CERA)
2020 Grant Recipient

Dr Flora Hui's Targeting Metabolic INsufficiency in Glaucoma (TAMING) with nicotinamide trial, aims to investigate whether daily treatment with high-dose nicotinamide (vitamin B3) could provide long-term protection against nerve cell damage and ultimately, whether it can prevent blindness in glaucoma. Dr Hui and her team have so far developed a new nicotinamide tablet to be used in the clinical trial use. Despite delays due to COVID, the team is currently in the process of finalising the supply of the tablets to be used in the trial. Dr Hui and her team have also designed a comprehensive clinical protocol which will not only look at changes to vision but also assess changes to quality of life.



Professor Jamie Craig,
Flinders University
2019 Grant Recipient

Professor Jamie Craig's research aims to provide evidence to show how major advances in the field of risk profiling – in particular, the glaucoma Polygenic Risk Score (PRS) test – can be effectively utilised to predict an individual's chances of developing glaucoma. To date, Professor Craig and his team have identified 107 genes that increase an individual's risk of developing glaucoma and have been able to develop a ground-breaking test. The PRS is now being developed by South Australian company Seonix, into a routine clinic test called 'SightScore'. Professor Craig hopes that during 2023, the SightScore test will be available in every optometrist, eye specialist or GP in the country.

FUNDRAISING HIGHLIGHTS & ACHIEVEMENTS

7 Sights in 7 Days Challenge

In 2022 Glaucoma Australia launched the 7 Sights in 7 Days Challenge, a fun and active fundraising event that the community and eye health industry can participate in every March to raise funds for early detection initiatives and patient education and support services. Participants were asked to find, snap and share seven themed sights to help 'take glaucoma blindness of the picture'. The photos of everyday moments shared by participants were a wonderful reminder of how precious our eyesight is.



End of Financial Year Appeal

The theme for the 2022 appeal was to save the sight of more Australians with supporters being encouraged to make a tax-deductible donation by June 30. Funds raised will be invested in patient education and support services.

Quinlivan Research Appeal

This appeal raises funds for the Quinlivan Research Grant which is awarded each year to Australian based glaucoma researchers to advance treatments and technologies and save sight. Professor Ewa Goldys was announced as the 2021 grant recipient for her research into novel imaging technology for the early detection and monitoring of glaucoma. We also shared an update on Dr Flora Hui's Vitamin B3 trial and the potential of nicotinamide.

Gifts In Wills

We have been privileged to receive charitable bequests from generous supporters who want to help future generations— precious gifts that will enable us to continue our vital work well into the future. Some gifts are earmarked for glaucoma research in our collective quest to find a cure and others are invested in initiatives that raise awareness and increase eye testing or specialised patient education and support services to save the sight of more Australians today.

We extend our gratitude to the following Bequestors and their families:


- The Estate of the Late Leslie Trevor Myers
- The Estate of the Late Irene Lily Barker
- The Estate of the Late David Douglas Dick
- The Estate of the Late Marjorie Grace Lawn
- The Estate of the Late Jacqueline Gal Turner
- The Estate of the Late Vera Mary Coulthard
- The Estate of the Late Hazel Garrett

**\$857,000
WAS
RAISED
DURING
2021/22**



Income Split

Almost \$857,000 was raised during the year up to 30 June 2022 which is broken down as follows:



- | | |
|----------------------------------|-------------------------|
| Bequests 41% | Trusts & Foundations 5% |
| Corporate Sponsorship 22% | Ordinary Donations 4% |
| 7 Sights in 7 days Challenge 13% | Subscriptions 2% |
| EOFY Appeal 8% | Merchandise 1% |
| Quinlivan Appeal 5% | |

THANK YOU

It is only through the support of generous individuals, corporations, foundations and organisations that Glaucoma Australia can continue to meet its objectives and realise its vision to eliminate glaucoma blindness. We are grateful for their support throughout 2021/2022.

Supporters

ASE IT
Beamers
Evolhope Family Trust
Glaukos
The Angles Family Foundation
Bequestors

Allied Partners

Brien Holden Vision Institute
Centre for Eye Research Australia
Healthdirect Australia
MedAdvisor
Oculo
Optometry Australia
Orthoptics Australia
Perth Eye Hospital
Pharmaceutical Society of Australia
RANZCO
Vision Australia
Vision 2020 Australia

We would also like to acknowledge the generous contributions of our amazing donors.

Special mentions

Ms Nathalie Quinlivan
Mr Mark Shepherd
Mr Bernard Sweeny
Mr Anthony Bourke
Mr Roger Moore
Mr David Coleman

Platinum Partners

abbvie

myhealth1st

Gold Partners

mivision
THE OPHTHALMIC JOURNAL

NOVAEYE
MEDICAL

shopper

Silver Partners

Specsavers

aspen
AUSTRALIA

BAUSCH+LOMB
See better. Live better.

Laubman&Pank
WE CARE FOR EYES

NOVARTIS
PHARMACEUTICALS

OPSM
LIFE. FOCUSED.



**“The eyes are
so precious...
but you do not
realise just
how precious
they are until
you’re having
fading eyesight”**

– Veronica

AWARENESS & ENGAGEMENT



Welcome David Koch!

Glaucoma Australia was thrilled to welcome one of Australia's best-known personalities David Koch as its newest Ambassador in June this year! By joining our sight-saving mission, David hopes to increase awareness and early detection for glaucoma by sharing his own glaucoma story and encouraging Australians to have their eyes checked regularly.


- Media and PR coverage of this announcement coordinated by Morey Media, reached an audience of over 7,901,179!
- A video of David encouraging Australians to 'Treat Your Eyes' to an eye test, reached over 2,000 people on our Facebook, Instagram, LinkedIn and YouTube channels.
- The 'Treat Your Eyes' campaign landing page had 559 pageviews in June (^831.67% from June 2021)

Identifying people at risk with our Risk Quiz

The Glaucoma Australia Risk Quiz which is promoted through paid and organic social media is designed to help raise awareness about glaucoma and identify people potentially at risk of developing this disease.

Between July 2021-June 2022 the quiz was completed by over 3000 people!

What we learnt:

- 98.7% of people who completed the risk quiz stated they had one or more known risk factors for developing glaucoma
 - 32.75% of people who completed the quiz have a family history of glaucoma
 - 78.58% of people stated they have regular eye tests every 1 – 2 years
 - 13.24% people who did not have regular eye tests, stated their attitude towards having a regular eye exam changed after the completing the quiz
- 


David Koch is one of Australia's best-known personalities, having co-hosted the Seven Network's Sunrise for the past 19 years.

David had no symptoms when he was diagnosed with glaucoma three years ago. The shock discovery is the driving force behind his involvement with Glaucoma Australia and his decision to publicly share his glaucoma diagnosis which reached over 7 million people in time for Men's Health Week.



Aussie music legend and Glaucoma Australia ambassador Kirk Pengilly fronted the 7 Sights in 7 Days Challenge in 2022.

He said “it’s a potent reminder that your sight enables you to do things you may take for granted, such as going for a run, riding a bike, snapping a photo or simply seeing your loved ones”.



Introducing: 7 Sights in 7 Days Challenge

In the lead up to World Glaucoma Week 2022 Glaucoma Australia launched its inaugural fundraiser the '7 Sights in 7 Days Challenge' which raised funds to support people living with glaucoma and increased awareness about the importance of attending regular eye tests.

- Promotional activity supported by Morey Media reached over 2.3 million people across TV, Radio, Print and Online.
- Television and radio interviews with Glaucoma Australia Ambassador and Aussie rock icon Kirk Pengilly aired on Channel 9 Today Extra, The Morning Show, 2GB, SBS Radio and Vision Australia Studio 1.
- Various news articles featuring Kirk Pengilly and case studies from three patients ran across 148 publications nationally.
- A 30 second radio Community Service Announcement featuring ambassador Kirk Pengilly ran 297 times in Sydney (2SM Sydney), Newcastle (2HD Newcastle) and Adelaide (FIVE AA Adelaide).
- Gold Sponsor Shopper Media donated over \$1.5 million in OOH media
- Gold Sponsor Mivision donated \$27,000 in print and digital media.

Our online store has a new look!

In March 2022 Glaucoma Australia migrated its online store to the Shopify ecommerce platform. By doing so revenue has increased 352.06% compared to the same period last year and new functionality has allowed the organisation to expand its product range through Drop Shipping, and make higher priced items more accessible by introducing Afterpay for customers.



GROWING AND ENGAGING OUR COMMUNITY

eNews subscribers: 10,142

Newsletter subscribers: 1,284

Website users: 45,164



Facebook followers: 4,870

Instagram followers: 1,455

LinkedIn followers: 943

Facebook Glaucoma

Support Group: 1,367

www

Facebook Congenital Glaucoma

Support Group: 291

11 Live Q&A events with industry experts on Facebook and YouTube received over 4,600 views!

To commemorate World Sight Day, our Patron, the Governor-General of Australia, His Excellency General the Honourable David Hurley AC DSC (Retd), announced the successful recipient of the 2021 Quinlivan Research Grant – Professor Ewa Goldys.



GOVERNANCE

Our Board

Maree O'Brien
GAICD, BA, Dip Teaching (Secondary)
President

Maree O'Brien is an Executive Consultant with extensive senior management and leadership experience. She is a strong business advocate, trusted advisor and able to see things from a range of stakeholder perspectives. Maree has a strong family history of glaucoma and is committed to Glaucoma Australia's mission to eliminate glaucoma blindness by increasing awareness of glaucoma in the community and encouraging people to have their eyes tested regularly.

Maree's business experience ranges from multinational technology and professional services companies through to small, specialised consulting companies that span Commercial, Government and Not-for-profit organisations, both internationally and in Australia.



Dr Benjamin Ashby
B.Optom (Hons) PhD GradCertOcTher GAICD
Vice President and Member of the Clinical Advisor Panel and Audit & Risk Committee

Dr Ashby has a family history of glaucoma, and he is involved in connecting glaucoma patients to Glaucoma Australia services. Dr Ashby is Director of Optometry for Specsavers Australia New Zealand with responsibility for clinical performance, optometry professional development, professional services and the development of clinical systems. He is actively involved in the research, development and implementation of sustainable models of eye care delivery that improve patient outcomes and reduce avoidable blindness. Dr Ashby also sits on Optometry Australia's glaucoma clinical guidelines working group, Deakin University Optometry Advisory Board, is an Adjunct Lecturer at UNSW and an Honorary Teaching Fellow at the University of Auckland.



Don Koch
M.Bus Banking & Finance, GAICD, Senior Fellow FINSIA, Fellow GIA
Honorary Treasurer and Member of the Media & Digital Technology and Audit & Risk Committees.

Don Koch is an experienced director with roles of Chair of BNK, Chair of Cache Investment Management a platform as a service startup, Chair of ResusRight a med tech startup, and a member of the governing board of the Cerebral Palsy Alliance Research Foundation.

Don also had over 40 years as a part of the Financial Services Industry in Australia and Internationally before transitioning to a directorship career.

Lynette Klein
B.Bus, AAICD
Honorary Secretary and Member of the Audit & Risk Committee

Lynette Klein has a family history of glaucoma and is passionate about increasing public health literacy on preventative health measures. Lynette has extensive experience working in the pharmaceutical and not for profit health sectors. She has worked in senior management roles at Bayer, Starlight Children's Foundation, Caltex and Qantas Airways.

She is also the founder of Arrive Collaborative management consultancy. Providing executive counsel to leaders on brand strategy, reputation management, communications, digital storytelling, marketing and fundraising strategies.



Dr Katherine Masselos
MB, BS(Hons), B.Optom, MPH, GAICD, FRANZCO
Chair of the Clinical Advisory Panel

Dr Masselos is an ophthalmologist with expertise in the diagnosis and management of glaucoma.

Dr Masselos performs both glaucoma and cataract surgery and has completed a fellowship in glaucoma at the Manchester Royal Eye Hospital in the United Kingdom. Dr Masselos works in private practice in Sydney and is a staff specialist at Prince of Wales and Sydney Eye Hospitals. She works with the Outback Eye Service to provide eye care to residents of Broken Hill and surrounding regions.

Dr Masselos is also a lecturer at the University of New South Wales.





Kirsten McKerrell
B.Pharm, B.Bus, GAICD
Member of the Clinical Advisor Panel and the Audit & Risk Committee

Kirsten McKerrell is a registered Pharmacist, and businesswoman who has owned and operated Community Pharmacies for over 20 years. She currently owns 3 pharmacies in Southeast Queensland. In addition to her experience in Community Pharmacy, Kirsten is also an Associate Lecturer at the School of Pharmacy at the University of Queensland.

Kirsten is interested in working with not-for-profit enterprises that have a focus on utilising education to improve health outcomes.



Satish Chandar
MBA (Executive)
Chair of the Media & Digital Technology Committee

Satish Chandar is an Independent Strategy and Management Consultant with extensive experience in developing and implementing business strategies and transformation programs across medium to large organisations in financial services industry as well as in the not-for-profit sector. With a career spanning over 30 years across multiple geographies, his current interests are in the cross-section of business, technology and digital strategies and advising on the associated challenges and opportunities.

With a strong family history of glaucoma, he is keen on supporting early detection and treatment of glaucoma across the general public.

William Peter Day
LLb. (Hons), MBA, FCA, FAICD
Chair of the Audit & Risk Committee

Peter Day has held senior Executive and Executive Director positions, mainly with the Rio Tinto Group and Bonlac Foods. He was Chief Financial Officer for Amcor for 7 years until 2007. Peter is a former Chairman of the Australian Accounting Standards Board and was Deputy Chairman of the Australian Securities & Investments Commission for two years.

He has served on private, public and for-purpose boards and is currently a non-executive Chair of two listed organisations, Alumina Limited and Australian Unity Office Fund.

He is also a director of Maurice Blackburn, a leading plaintiff law firm. He has also supported professional education initiatives plus health and disability services through board and volunteer roles. He has a family member who is under treatment for glaucoma.



James Christensen
Stepped down June 2022

James is a co-owner and Director of OptiMed Pty Ltd, a major ophthalmic supplier of specialised diagnostic products in Australia and New Zealand. Prior to this role, James held technical support and sales positions with OPSM and Rodenstock and has a background in research in the School of Optometry at the Queensland University of Technology.



OUR COMMITTEES

Clinical Advisory Panel

The Clinical Advisory Panel is a committee of the Glaucoma Australia Board and supports the board with its aim to prevent visual loss among patients with glaucoma. It is comprised of health care providers including Ophthalmologists, Optometrists and Pharmacists.

- Dr Katherine Masselos (Ophthalmologist) – Chair
- Dr David Wechsler (Ophthalmologist)
- Dr Nelson Kuo (Ophthalmologist)
- Dr Mark Chiang (Ophthalmologist)
- Dr Jennifer Fan-Gaskin (Ophthalmologist)
- Dr Brian Ang (Ophthalmologist)
- Dr Geoffrey Chan (Ophthalmologist)
- Dr Ben Ashby (Optometrist)
- Peter Murphy (Optometrist)
- Inez Hsing (Optometrist)
- Ho Wah Ng (Optometrist)
- Anna Delmadoros (Optometrist)
- Janelle Tong (Optometrist)
- Kirsten McKerrell (Pharmacist)
- Debbie Rigby (Pharmacist)
- Han Fey Yap (Pharmacist)
- Jessica Leung (Pharmacist)
- Khanh Nguyen (Pharmacist)
- Mariyam Aly (Pharmacist)
- Dan Hillier (Pharmacist)
- Nhan Do (Pharmacist)

Audit and Risk Committee

The Audit and Risk Committee is a committee of the Glaucoma Australia Board and assists the board in fulfilling its responsibilities regarding oversight of the audit and risk requirements of Glaucoma Australia and other stakeholders to meet current and future developments in line with the Strategic Plan.

- William Peter Day – Chair
- Kirsten McKerrell
- Lynette Klein
- Richard Wylie (GA representative)

Media and Digital Technology Committee

The Media and Digital Technology (M&DT) Committee is a committee of the Glaucoma Australia Board and assists the board in fulfilling its responsibilities regarding oversight of the digital and technology requirements of Glaucoma Australia and other stakeholders to meet current and future developments in line with the Strategic Plan.

- Satish Chandar – Chair
- Don Koch
- Richard Wylie (GA representative)
- Gillian Hopkins (GA representative)



**Glaucoma
Australia**
Saving sight